10x Genomics Q3 revenue $149M (-2% YoY); guides Q4 $154-158M

10x Genomics, Inc.

2025-Q3 EPS reported -$0.22 revenue$476,793,000

Revenue $149.0M in Q3 2025, down 2% YoY; gross margin 67% vs 70% prior year.
Operating loss improved to $32.2M from $41.5M; net loss $27.5M vs $35.8M.
Cash and marketable securities $482.1M, up $35M sequentially.
Q4 2025 revenue guidance $154-158M (midpoint 6% decline YoY, 5% sequential growth).
Launched next-gen Chromium Flex and Xenium Protein spatial multiomic workflow.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.